ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 36 of 48
Up
УЖМБС 2018, 3(2): 208–216
https://doi.org/10.26693/jmbs03.02.208
Medicine. Reviews

Studying the Main Issues of Contrast-Induced Nephropathy (Review of Literature)

Pustovoyt A. L., Yarmola T. I., Talash V. V., Tkachenko L. A., Kostrikova U. A.
Abstract

The authors carried out a general analysis of literature data on the problem of contrast-induced nephropathy. On modern presentations pre-procedural methods of prophylaxis contrast-induced nephropathy must include: Abolition of nephrotoxic preparations a 3 twenty-four hours prior to procedure. Application of contrasting preparation of izo- or hypoosmolary is with a calculation minimum of effective volume of preparation. Materials and Methods. We carried out determination of kreatinine, urea, electrolytes 3-4 twenty-four hours prior to and during 48-72 hours after an inspection. Hydratation of 0,9% of NaCl or 4% bicarbonate of natrium intravenous 1 ml/kg/hour during 6-12 hours before procedure and during 12-24 hours after it. Setting of N- of acetylcystein is 600 mgs (1200 mgs – at chronic illness of kidneys and diabetes mellitus) perorally 2 times on twenty-four hours, before procedure and in the day of procedure or 150 mg/kg intravenous during 5 hour it is recommended to use low or izoosmolary X-ray contrast facilities of the last generations and, at possibility, to use necessary doses minimum. Results and Discussion. Thus, contrast-induced sharp damage of kidneys is serious, prognostic unfavorable complication undertaking an X-ray contrast study, however is prognostic enough disease. During the determination of stratification severity of acute kidney injury it is necessary to take into account the initial level of kidneys functional ability. In the category of highest risk for contrast-induced nephropathy get patients with kidney disease have elevated levels of serum creatinine, as well as people with diabetes mellitus, especially in the elderly. In most cases, an X-ray contrast test is a planned procedure and the clinical significance of the kidney damage problem can be minimized in identifying patients at risk, assessing the risk / benefit in choosing the most informative and safe research method, correcting the risk factors, provided to modification and implementation of preventive measures.

Keywords: X-ray contrast preparations, contrast-induced nephropathy, acute renal damage, risk factors

Full text: PDF (Ukr) 248K

References
  1. Vatutin NT, Zinkovich MI. Kontrast-indutsirovannaya nefropatiya (obzor literatury i sobstvennye dannye). Bukovinskiy medichniy visnik. 2015; 19 (2/74): 220-5. [Russian]
  2. Vatutin NT. Neotlozhnaya kardiologiya. Donetsk: FO-P; 2011. 236 s. [Russian]
  3. Volgina GV. Kontrast-indutsirovannaya nefropatiya: patogenez, faktory riska, strategiya profilaktiki. Nefrologiya i dializ. 2006; 8 (2): 176-83. [Russian]
  4. Guskova EV. Faktory, opredelyayushchie bezopasnost dvoynoy antitrombotsitarnoy terapii posle planovykh chreskozhnykh koronarnykh vmeshatnlstv : dis. … kand. med. nauk, Abstr. PhDr. (Med.). M; 2016. 159 s. [Russian]
  5. Dunaeva AR, Shcherbakova AS, Khafizov TN, i dr. Kontrast-indutsirovannaya nefropatiya pri koronaroangiografii. Prakticheskaya meditsina. 2014; 3 (79): 35-40. [Russian]
  6. Dundua DP, Babunashvili AM, i dr. Sravnenie rentgenokontrastnykh preparatov po nefrotoksichnosti: rezultaty randomizirovannogo issledovaniya. Mezhdunarodnyy zhurnal interventsionnoy kardioangiologii. 2010; 20: 26-33. [Russian]
  7. Zerbino DD. Khimicheskie bolezni. Likuvannya ta diagnostika. 2003; 4: 10-3. [Russian]
  8. Ivanov DD, Korzh OM. Nefrologiya v praktitsi simeynogo likarya: navch-metod posibnik. 3-e vid, pererobl. Donetsk: Vidavets Zaslavskiy OYu, 2014. s. 366-9; 394-405. [Ukrainian]
  9. Kitayev VM, Kitayev SV.Rentgenkontrastnye preparaty: diagnosticheskaya effektivnost i bezopasnost. Meditsinskaya vizualizatsiya. 2001; 2: 115-20. [Ukrainian]
  10. Kobalava ZhD, Bobkova IN, Villevalde SV, i dr. Klinicheskie rekomendatsii «Serdechno-sosudistyy risk i khronicheskaya bolezn pochek: strategii kardio-nefroprotektsii». Rossiyskiy kardiologicheskiy zhurnal. 2014; 8 (112): 7-37. [Russian]
  11. Kolesnikov SV, Borisov AS. Biomarkery ostrogo pochechnogo povrezhdeniya: klinicheskie aspekty. Nefrologiya i dializ. 2013; 15 (3): 184-90. [Russian]
  12. Kutsenko SA. Osnovy toksikologii. Sankt-Peterburg, 2002. 119 s. [Russian]
  13. Mikhalchenko OM, Stelmashchuk VP. Kontrast-indukovana nefropatiya. Faktori riziku. Kriteriyi diagnostiki. Profilaktika. Ukrayina. Zdorovʼya natsiyi. 2013; 3 (27): 68-74. [Ukrainian]
  14. Nefrologiya: nats rukovodstvo. Glavnyy redaktor NA Mukhin; otvetstvennyy redaktor VV Fomin; Nauchnoe obshchestvovo nefrologov Rossii, Assotsiatsii med obshchestv po kachestvu. M: GEOTAR-Media, 2009. 716 s. [Russian]
  15. Proekt Nastanova: khronichna khvoroba nirok, osnovni polozhennya, viznachennya, diagnostika, skrining, pidkhodi do profilaktiki ta likuvannya. Robocha grupa Ukrayinskoyi asotsiatsiyi nefrologiv. Kiyiv, 2017. 46 s. [Ukrainian]
  16. Semidotskaya ZhD, Chernyakova IA, Pionova EN, i dr. Ostroe povrezhdenie pochek: sovremennyy vzglyad na problemu. Skhidnoyevropeyskiy zhurnal vnutrishnoyi ta simeynoyi meditsini. 2017; 1: 10-6. [Russian]
  17. Non-ST- Elevation Myocardial Infarction. ACCF 2011/ AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina. Circulation. 2011; 123: 2039-40.
  18. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011; 124 (11): 1250-9. https://www.ncbi.nlm.nih.gov/pubmed/21859972. https://doi.org/10.1161/CIRCULATIONAHA.111.038943
  19. Agrawal M, Stouffer GA. Contrast-induced nephropathy after angiography. Am Med Sci. 2002; 323 (5): 252–5. https://doi.org/10.1097/00000441-200205000-00004
  20. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003; 348 (6): 491-9. https://doi.org/10.1056/NEJMoa021833
  21. Barrett BJ, Parfrey PS. Clinical practice. Preventing Nephropathy Induced by Contrast Medium. N Engl J Med. 2006; 354 (4): 379–86. https://www.ncbi.nlm.nih.gov/pubmed/16436769. https://doi.org/10.1056/NEJMcp050801
  22. Bellomo R, Ronco C, kellum JA, et al. Acute renal failure — definition, outcome, measures, animae models, fluid therapy and information technology needs: The second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2008; 8 (4): 204-12. https://www.ncbi.nlm.nih.gov/pubmed/15312219. https://www.ncbi.nlm.nih.gov/pmc/articles/522841. https://doi.org/10.1186/cc2872
  23. Bouman C, Kellum JA, Levin N. Definition of acute renal failure. Acute Dialisis Quality Initiative. 2nd International Consensus Conference, National Kidney Foundation KD: Clinical practice guidelines for chronic Kidney Disease: Evaluation, classification and stratification. 2002; 39 (Suppl 1): 1-266.
  24. Budhiraja P, Chen Z, Popovtzer M. Sodium bicarbonate versus normal saline for protection against contrast nephropathy. Ren Fail. 2009; 31 (2): 118-23. https://www.ncbi.nlm.nih.gov/pubmed/19212908. https://doi.org/10.1080/08860220802599239
  25. Caruso M, Balasus F, Incalcaterra E, Ruggieri A, Evola S, Fattouch K, Bracale UM, Amodio E, Novo G, Andolina G, Novo S.. Contrast-induced nephropathy after percutaneous coronary intervention in simple lesions: risk factors and incidence are affected by the definition utilized. Intern Med. 2011; 50 (9): 983-9. https://www.ncbi.nlm.nih.gov/pubmed/21532220. https://doi.org/10.2169/internalmedicine.50.4976
  26. Cowburn PJ, Patel H, Pipes RR, Parker JD. Contrast nephropathy post cardiac resynchronization therapy: an under-recognized complication with important morbidity. Eur J Heart Fail. 2005; 7 (5): 899-903. https://www.ncbi.nlm.nih.gov/pubmed/15919239. https://doi.org/10.1016/j.ejheart.2004.10.023
  27. Cox CD, Tsikouris JP. Preventing contrast nephropathy: what is the best strategy? A review of the literature. J Clin Pharmacol. 2004; 44: 327–37. https://www.ncbi.nlm.nih.gov/pubmed/15051739. https://doi.org/10.1177/0091270004263466
  28. Detrenis S, Meschi M, Bertolini L, Savazzi G. Contrast medium administration in the elderly patient: is advancing age an independent risk factor for contrast nephropathy after angiographic procedures? J Vasc Interv Radiol. 2007; 18 (2): 177-85. https://www.ncbi.nlm.nih.gov/pubmed/17327549. https://doi.org/10.1016/j.jvir.2006.12.009
  29. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado César LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant. 2004; 19 (7): 1803-7. https://www.ncbi.nlm.nih.gov/pubmed/15128882. https://doi.org/10.1093/ndt/gfh261
  30. The ad-hoc working group of ERBP: Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W. European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012; 27 (12): 4263–72. https://www.ncbi.nlm.nih.gov/pmc/articles/3520085. https://doi.org/10.1093/ndt/gfs375
  31. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005; 172 (11): 1461-71. https://www.ncbi.nlm.nih.gov/pubmed/15911862. https://www.ncbi.nlm.nih.gov/pmc/articles/557983. https://doi.org/10.1503/cmaj.1040847
  32. Jorgensen AL. Contrast-induced nephropathy: pathophysiology and preventive strategies. Crit Care Nurse. 2013; 33 (1): 37-46. https://www.ncbi.nlm.nih.gov/pubmed/23377156. https://doi.org/10.4037/ccn2013680
  33. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012; 2 (1). Available from: www. kdigo.org/clinical_practice_guidelines.
  34. Koch JA, Plum J, Grabensee B, Mödder U. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant. 2000; 15 (1): 43-9. https://www.ncbi.nlm.nih.gov/pubmed/10607766. https://doi.org/10.1093/ndt/15.1.43
  35. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004; 7: 1393-9. https://www.ncbi.nlm.nih.gov/pubmed/15464318. https://doi.org/10.1016/j.jacc.2004.06.068
  36. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006; 100: 11-5. https://www.ncbi.nlm.nih.gov/pubmed/16612394. https://doi.org/10.1038/sj.ki.5000368
  37. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013; 382 (9906): 1714-22. https://www.ncbi.nlm.nih.gov/pubmed/24004642. https://doi.org/10.1016/S0140-6736(13)61720-1
  38. Jaipaul N, Manalo R, Sadjadi SA, McMillan J. Obesity is not associated with contrast nephropathy. J Ther Clin Risk Manag. 2010; 6: 213-7. https://www.ncbi.nlm.nih.gov/pubmed/20526376. https://www.ncbi.nlm.nih.gov/pmc/articles/2878954. https://doi.org/10.2147/TCRM.S10198
  39. Patel K, King CA, Jovin IS. Angiotensin-converting enzyme inhibitors and their effects on contrast-induced nephropathy after cardiac catheterization or percutaneous coronary intervention. Cardiovasc Revasc Med. 2011; 12 (2): 90-3. https://www.ncbi.nlm.nih.gov/pubmed/21421186. https://doi.org/10.1016/j.carrev.2010.01.002
  40. Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol. 2008; 40 (3): 749-55. https://www.ncbi.nlm.nih.gov/pubmed/18438718. https://doi.org/10.1007/s11255-008-9368-1
  41. Rudnick M, Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? Clinical Journal of the American Society of Nephrology. 2008; 3 (1): 263–72. https://www.ncbi.nlm.nih.gov/pubmed/18178787. https://doi.org/10.2215/CJN.03690907
  42. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006; 113 (14): 1799-806. https://www.ncbi.nlm.nih.gov/pubmed/16606801. https://doi.org/10.1161/CIRCULATIONAHA.105.595090
  43. Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast induced nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2011; 33 (4): 344-51. https://www.ncbi.nlm.nih.gov/pubmed/21430372. https://doi.org/10.1159/000326269